Protection for cancer patients

The T-cell activator "CoVac-1" offers the particularly vulnerable group of immunocompromised individuals sustained protection against coronavirus.
Credit: Beate Armbruster / University Hospital of Tuebingen

Tübingen T-cell activator offers protection against coronaviruses in immunocompromised patients.

Good news for patients with acquired or congenital immunodeficiency: The results of a clinical phase II study at the University Hospital Tübingen led by Prof. Dr. Juliane Walz and Prof. Dr. Helmut Salih show an effective activation of T cells against the coronavirus. After positive results in healthy volunteers in the previous phase I, the T-cell activator “CoVac-1” was now able to reproduce these effects in cancer patients for the first time. The results have been published in the renowned journal Nature communications.

Even after the end of the COVID-19 pandemic, viral infections such as SARS-CoV-2 pose a serious threat to patients with weakened immune systems. This group includes, in particular, cancer patients who, due to their disease itself or due to tumor therapy, are unable to mount an adequate immune response following natural infection or with conventional vaccines. These patients often do not develop antibodies against the viral disease. For this reason, the Tübingen team has developed a vaccine with the aim of better protecting immunocompromised patients against infectious diseases. This vaccine specifically activates T cells, which are another important component of our immune system and play a decisive role in the defense against infectious diseases.

For this purpose, the novel T cell activator CoVac-1 was used, which in itself is being developed for cancer immunotherapy, one of the main research focuses of the Tübingen immunologists. As early as 2022, CoVac-1 was successfully tested on healthy volunteers and showed good tolerability with very good immune stimulation, i.e. very strong activation of T cells.

Results of the Phase II study

A total of 54 patients were vaccinated once as part of the study. Most of the study participants suffered from blood cancers and showed a significantly weakened immune system due to the disease itself or the tumor therapy. There were little to no side effects. Only a few mild complaints such as headaches and fatigue were reported. Local induration developed at the vaccination site in all subjects. “This local reaction is expected and desired for our T-cell activator. It is an expression of the formation of a depot at the vaccination site, which prevents rapid degradation of the T-cell response and thus enables a long-lasting immune response,” explains Dr. Jonas Heitmann, one of the study’s first authors.

The long-lasting effect is particularly noteworthy. Thus, even four weeks after vaccination, the broad and strong T-cell immune response was detected. In initial follow-up studies, these immune responses remained unchanged in strength. Even in severely immunocompromised patients, the T-cell responses activated by CoVac-1 are significantly more pronounced than in recovered individuals after natural infection and also more potent than the T-cell immunity generated by licensed mRNA or vector vaccines.

In-house vaccine development, manufacturing and testing

CoVac-1 is produced in the drug peptide laboratory and the so-called GMP unit of the University Hospital and Medical Faculty in Tübingen. Here, too, the long-standing experience and expertise in the production of vaccines for cancer patients is being drawn upon. The clinical evaluation of the T-cell activator is carried out in the KKE Translational Immunology, a unique facility in Germany in the Department of Internal Medicine of the University Hospital. It was established to test innovative immunotherapy concepts as quickly as possible in initial clinical trials so that patients can benefit from new research findings as quickly as possible. The study was also conducted under the direction of the University Hospital Tübingen at hospitals in Frankfurt am Main and the Charité in Berlin.

Further development of T-cell activators

Based on these encouraging results, the team is already working on the development of vaccines using T-cell activators against numerous other infectious diseases that pose a threat to immunocompromised tumor patients. In addition, this study also provides an important contribution to the development of therapeutic vaccines for affected individuals, which are currently already being investigated in patients with various solid tumors and blood cancers.

Originalpublikation:

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency; doi: https://doi.org/10.1038/s41467-023-40758-0

http://www.medizin.uni-tuebingen.de/

Media Contact

Bianca Hermle Kommunikation und Medien
Universitätsklinikum Tübingen

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Pancreatic cancer’s cellular amnesia

Things aren’t always as they seem. Take pancreatic cancer, for example. In up to one in 10 cases, researchers have documented a peculiar characteristic. Some of the pancreatic cells appear…

Innovative Polymer Wound Dressings for Painless and Residue-Free Removal

A new approach enables dressings that adhere firmly to the skin at body temperature, but can be removed easily and painlessly in combination with a cold pack. The dressing adheres…

SETI Institute launches groundbreaking technosignature science and technology

Application deadline for grants is July 15, 2024. The SETI Institute is announcing the launch of a pioneering grants program dedicated to advancing technosignature science. This first-of-its-kind initiative aims to…

Partners & Sponsors